{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:27Z","timestamp":1791492687362,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Galapagos NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2026.152946","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:02:00Z","timestamp":1770912120000},"page":"152946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study): effect of regulatory warnings"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-8395","authenticated-orcid":false,"given":"Denis","family":"Mongin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Aymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Coupal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sella","family":"Provan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Fritsch-Stork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Z\u00e1vada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pombo-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Otero-Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine S.","family":"Courvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Furer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152946_bib0001","unstructured":"New rheumatoid arthritis drug targets NIH-discovered protein. National Institutes of Health (NIH). September 24, 2015. Accessed November 28, 2024. https:\/\/www.nih.gov\/news-events\/news-releases\/new-rheumatoid-arthritis-drug-targets-nih-discovered-protein."},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152946_bib0002","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152946_bib0003","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"10093","key":"10.1016\/j.semarthrit.2026.152946_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152946_bib0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152946_bib0006","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152946_bib0007","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152946_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152946_bib0009","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152946_bib0010","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis & Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152946_bib0011","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New England J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152946_bib0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0013","series-title":"FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0014","unstructured":"Janus kinase inhibitors (JAKi) - referral | European Medicines Agency (EMA). May 22, 2023. Accessed November 28, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152946_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.semarthrit.2026.152946_bib0016","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/jcm13133929","article-title":"Influence of safety warnings on the prescribing attitude of JAK inhibitors for rheumatoid arthritis in Italy","volume":"13","author":"Paroli","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152946_bib0017","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2665-9913(24)00002-X","article-title":"The influence of safety warnings on the prescribing of JAK inhibitors","volume":"6","author":"Russell","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152946_bib0018","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152946_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question \u2013 data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152946_bib0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study)","volume":"83","author":"Aymon","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0021","doi-asserted-by":"crossref","unstructured":"Aymon R, Mongin D, Guemara R, et al. Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries. Arthritis & Rheumatol. n\/a(n\/a). doi:10.1002\/art.43188.","DOI":"10.1002\/art.43188"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0022","series-title":"Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0023","unstructured":"Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis | European Medicines Agency (EMA). March 20, 2019. Accessed October 25, 2024. https:\/\/www.ema.europa.eu\/en\/news\/increased-risk-blood-clots-lungs-and-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis."},{"key":"10.1016\/j.semarthrit.2026.152946_bib0024","unstructured":"EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots | European Medicines Agency (EMA). November 15, 2019. Accessed October 25, 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots."},{"key":"10.1016\/j.semarthrit.2026.152946_bib0025","series-title":"Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)","year":"2021"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0026","series-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0027","series-title":"ACR Meeting Abstracts","article-title":"Incidence of infections in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of Tofacitinib vs TNF inhibitors","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0028","series-title":"ACR Meeting Abstracts","article-title":"Safety and efficacy of Tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: results from a phase 3b\/4 randomized Safety trial","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0029","series-title":"ACR Meeting Abstracts","article-title":"Risk factors for major adverse cardiovascular events in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular Risk factor: results from a phase 3b\/4 randomized safety study of Tofacitinib vs TNF inhibitors","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0030","series-title":"ACR Meeting Abstracts","article-title":"Malignancies in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of Tofacitinib vs TNF inhibitors","year":"2024"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0031","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency (EMA). October 28, 2022. Accessed October 25, 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders."},{"issue":"19","key":"10.1016\/j.semarthrit.2026.152946_bib0032","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/sim.1545","article-title":"Estimating regression models with unknown break-points","volume":"22","author":"Muggeo","year":"2003","journal-title":"Statist Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152946_bib0033","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/aje\/kwm223","article-title":"A modified least-squares regression approach to the estimation of risk difference","volume":"166","author":"Cheung","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2026.152946_bib0034","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152946_bib0035","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review","volume":"50","author":"Dusetzina","year":"2012","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152946_bib0036","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/bcp.14104","article-title":"Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: systematic review, time series analysis and meta-analysis","volume":"86","author":"Weatherburn","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152946_bib0037","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s10067-024-07099-9","article-title":"National and interprovincial prescribing patterns of JAK-inhibitors in Canada: a repeated cross-sectional analysis","volume":"43","author":"Saunders","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152946_bib0038","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead395","article-title":"The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort","volume":"63","author":"Tomelleri","year":"2024","journal-title":"Rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:41:56Z","timestamp":1791492116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"alternative-id":["S0049017226000351"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152946","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study): effect of regulatory warnings","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152946"}}